Omega-3 fatty acids improve recovery, whereas omega-6 fatty acids worsen outcome, after spinal cord injury in the adult rat

被引:151
作者
King, VR [1 ]
Huang, WL [1 ]
Dyall, SC [1 ]
Curran, OE [1 ]
Priestley, JV [1 ]
Michael-Titus, AT [1 ]
机构
[1] Queen Mary Univ London, Inst Cell & Mol Sci, St Bartholomews & Royal London Sch Med & Dent, Ctr Neurosci, London E1 2AT, England
关键词
spinal cord injury; neuroprotection; omega-3 fatty acids; apoptosis; inflammation; oxidation;
D O I
10.1523/JNEUROSCI.5539-05.2006
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Spinal cord injury (SCI) is a cause of major neurological disability, and no satisfactory treatment is currently available. Evidence suggests that polyunsaturated fatty acids (PUFAs) could target some of the pathological mechanisms that underlie damage after SCI. We examined the effects of treatment with PUFAs after lateral spinal cord hemisection in the rat. The omega-3 PUFAs alpha-linolenic acid and docosahexaenoic acid (DHA) injected 30 min after injury induced significantly improved locomotor performance and neuroprotection, including decreased lesion size and apoptosis and increased neuronal and oligodendrocyte survival. Evidence showing a decrease in RNA/DNA oxidation suggests that the neuroprotective effect of omega-3 PUFAs involved a significant antioxidant function. In contrast, animals treated with arachidonic acid, an omega-6 PUFA, had a significantly worse outcome than controls. We confirmed the neuroprotective effect of omega-3 PUFAs by examining the effects of DHA treatment after spinal cord compression injury. Results indicated that DHA administered 30 min after spinal cord compression not only greatly increased survival of neurons but also resulted in significantly better locomotor performance for up to 6 weeks after injury. This report shows a striking difference in efficacy between the effects of treatment with omega-3 and omega-6 PUFAs on the outcome of SCI, with omega-3 PUFAs being neuroprotective and omega-6 PUFAs having a damaging effect. Given the proven clinical safety of omega-3 PUFAs, our observations show that these PUFAs have significant therapeutic potential in SCI. In contrast, the use of preparations enriched in omega-6 PUFAs after injury could worsen outcome after SCI.
引用
收藏
页码:4672 / 4680
页数:9
相关论文
共 47 条
[1]   Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection [J].
Basso, DM ;
Beattie, MS ;
Bresnahan, JC .
EXPERIMENTAL NEUROLOGY, 1996, 139 (02) :244-256
[2]  
Bazan NG, 2005, BRAIN PATHOL, V15, P159
[3]   Review of current evidence for apoptosis after spinal cord injury [J].
Beattie, MS ;
Farooqui, AA ;
Bresnahan, JC .
JOURNAL OF NEUROTRAUMA, 2000, 17 (10) :915-925
[4]   Polyunsaturated fatty acids induce ischemic and epileptic tolerance [J].
Blondeau, N ;
Widmann, C ;
Lazdunski, M ;
Heurteaux, C .
NEUROSCIENCE, 2002, 109 (02) :231-241
[5]   Long-chain n-3 fatty acids and inflammation: potential application in surgical and trauma patients [J].
Calder, PC .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2003, 36 (04) :433-446
[6]   Docosahexaenoic acid promotes neurite growth in hippocampal neurons [J].
Calderon, F ;
Kim, HY .
JOURNAL OF NEUROCHEMISTRY, 2004, 90 (04) :979-988
[7]   Protective effice of chronic ethyl docosahexaenoate administration on brain injury in ischemic gerbils [J].
Cao, DH ;
Xu, HF ;
Xue, RH ;
Zheng, WF ;
Liu, ZL .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2004, 79 (04) :651-659
[8]   α-Linolenic acid does not contribute appreciably to docosahexaenoic acid within brain phospholipids of adult rats fed a diet enriched in docosahexaenoic acid [J].
DeMar, JC ;
Ma, KZ ;
Chang, L ;
Bell, JM ;
Rapoport, SI .
JOURNAL OF NEUROCHEMISTRY, 2005, 94 (04) :1063-1076
[9]   SECONDARY CELL-DEATH AND THE INFLAMMATORY REACTION AFTER DORSAL HEMISECTION OF THE RAT SPINAL-CORD [J].
DUSART, I ;
SCHWAB, ME .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1994, 6 (05) :712-724
[10]   Clinical potential of omega-3 fatty acids in the treatment of schizophrenia [J].
Emsley, R ;
Oosthuizen, P ;
van Rensburg, SJ .
CNS DRUGS, 2003, 17 (15) :1081-1091